Physician profile
Karla Aleman
NPI 1366149239
$3,156.78
in general payments reported to CMS, 2019-2025
23 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $728 · 2024: $810 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,082 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,081.79 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.02 | 2024-2025 | |
| Janssen Biotech, INC. | $544.34 | 2023-2025 | Tremfya, Tecvayli, Simponi Aria |
| Daiichi Sankyo INC. | $417.37 | 2023-2024 | Enhertu |
| Lilly USA, LLC | $323.91 | 2025 | Omvoh |
| Gilead Sciences, INC. | $229.98 | 2023-2024 | Trodelvy |
| Pfizer INC. | $186.65 | 2024-2025 | |
| Eisai INC. | $120.56 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $117.56 | 2023 | Imfinzi |
| Alnylam Pharmaceuticals INC. | $89.72 | 2025 | Amvuttra |
| Lundbeck LLC | $69.91 | 2025 | Vyepti |
| Merck Sharp & Dohme LLC | $64.81 | 2023-2025 | Keytruda, Welireg |
| Genzyme Corporation | $61.01 | 2023-2024 | |
| Neurelis, INC. | $59.57 | 2025 | Valtoco |
| Ipsen Biopharmaceuticals, INC | $52.23 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $43.57 | 2024 | Resmetirom |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $36.76 | 2025 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $33.84 | 2025 | Voquezna |
| Urogen Pharma, INC. | $29.37 | 2025 | |
| Novo Nordisk INC | $28.57 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $26.68 | 2025 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $22.91 | 2025 | Entyvio |
| Ardelyx, INC. | $20.06 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $19.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Aleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.